Abstract 2086P
Background
Management of opioids use disorder in cancer survivors The morbidity and mortality associated with opioid use disorder is a public health concern in many countries. However, opioids are a cornerstone in the management of cancer pain. The problem of opioid use disorders is an emerging concern in cancer survivors.
Methods
Over 10 months, we evaluated at the Gustave Roussy Pain Management Unit survivors of cancer who were on long-term prescription opioid therapy. A thorough evaluation involving an addiction specialist doctor, a psychologist or a psychiatrist, and the pain team was conducted to answer the following questions: - What is the current painful complaint and are opioids the adequate treatment for it? - Is the patient dependent on prescription opioids and does he/she have prescription opioid misuse? - Does the patient have an addiction to opioids (according to DSMV criteria) A personalized therapeutic project was then proposed for each patient.
Results
All patients accepted the project. Thirteen patients with a prescription opioid use disorder were enrolled for an opioid withdrawal program. Nine patients were misusing step-3 analgesics as defined by the WHO analgesic ladder, including one patient misusing fast-acting fentanyl, and 4 were misusing step-2 analgesics as monotherapy or in combination with another step-2 analgesic. The mean oral morphine equivalent doses were 150 mg daily [40-480 mg]. Nine patients had an opioid prescription renewal for more than 5 years. The fear of the pain rebound was the main obstacle to stopping opioid use. Seven patients could be withdrawn as outpatients six required hospitalizations for withdrawal under strict medical supervision. Five patients were put on Medications for Opioid Use Disorder (MOUD). None of the residual pain complaints warranted an opioid prescription.
Conclusions
Prescription opioids use disorder in cancer survivors requires the intervention of a specialized multidisciplinary team, trained in the identification and treatment of opioid withdrawal, in the handling of MOUD and in the management of chronic pain diseases. Close and regular collaboration with oncologists is necessary, to reconsider the need for prescription opioids in every patient as soon as he/she is in remission.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Gustave Roussy Cancer Campus Grand Paris.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06
2115P - Pre-cachexia incidence in patients with solid cancer: A cross-sectional study
Presenter: Lynn Gottmann
Session: Poster session 06